Effectiveness of nanofiltration in removing small non‐enveloped viruses from three different plasma‐derived products

The objective of this study was to assess the ability of nanofiltration of albumin solution, prothrombin complex (PTC) and factor IX (FIX) to remove two small, non‐enveloped DNA viruses, parvovirus B19 (B19V) and torque teno virus (TTV). Virus removal was investigated with down‐scale experiments performed with sequential steps of 35‐nm and 15‐nm nanofiltrations of products spiked with virus DNA‐positive sera. Viral loads were determined by real‐time PCRs. The 15‐nm nanofiltration removed more than 4.0 B19V log from all the products, TTV was reduced of more than 3.0 log from albumin solution and FIX by 35‐nm and 15‐nm nanofiltrations, respectively, being viral DNA undetectable after these treatments. Traces of TTV were still found in PTC after the 15‐nm nanofiltration. In conclusion, nanofiltration can be efficacious in removing small naked viruses but, since viruses with similar features can differently respond to the treatment, a careful monitoring of large‐scale nanofiltration should be performed.

[1]  J. Modrof,et al.  Inactivation of parvovirus B19 during STIM‐4 vapor heat treatment of three coagulation factor concentrates , 2008, Transfusion.

[2]  J. Blümel,et al.  Kinetics of inactivating human parvovirus B19 and porcine parvovirus by dry‐heat treatment , 2008, Transfusion.

[3]  C. Kempf,et al.  Molecular mechanism underlying B19 virus inactivation and comparison to other parvoviruses , 2007, Transfusion.

[4]  A. Wieser,et al.  Removal of small nonenveloped viruses by antibody‐enhanced nanofiltration during the manufacture of plasma derivatives , 2006, Transfusion.

[5]  K. Zakrzewska,et al.  Different behavior of erythrovirus B19 and torquetenovirus in response to a single step of albumin purification , 2006, Transfusion.

[6]  J. Löwer,et al.  Different susceptibility of B19 virus and mice minute virus to low pH treatment , 2004, Transfusion.

[7]  N. Fujii,et al.  Removal of small non‐enveloped viruses by nanofiltration , 2004, Vox sanguinis.

[8]  A. Boner,et al.  TT Virus in the Nasal Secretions of Children with Acute Respiratory Diseases: Relations to Viremia and Disease Severity , 2003, Journal of Virology.

[9]  T. Burnouf,et al.  Nanofiltration of plasma‐derived biopharmaceutical products , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  C. Kempf,et al.  Removal of neutralized model parvoviruses and enteroviruses in human IgG solutions by nanofiltration , 2002, Transfusion.

[11]  J. Löwer,et al.  Inactivation of parvovirus B19 during pasteurization of human serum albumin , 2002, Transfusion.

[12]  A. Groener,et al.  Effectiveness of alternative treatments for reducing potential viral contaminants from plasma-derived products. , 2002, Thrombosis research.

[13]  G. Antonelli,et al.  Dynamics of Persistent TT Virus Infection, as Determined in Patients Treated with Alpha Interferon for Concomitant Hepatitis C Virus Infection , 2001, Journal of Virology.

[14]  D. Josić,et al.  Manufacturing of a prothrombin complex concentrate aiming at low thrombogenicity. , 2000, Thrombosis research.

[15]  A. Losikoff,et al.  Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration. , 1998, Biologicals : journal of the International Association of Biological Standardization.

[16]  D. Josić,et al.  Improved virus safety and purity of a chromatographically produced factor IX concentrate by nanofiltration. , 1995, Journal of chromatography. B, Biomedical applications.

[17]  C. Michalski,et al.  Large‐Scale Production and Properties of a Solvent‐Detergent‐Treated Factor IX Concentrate from Human Plasma , 1988, Vox sanguinis.

[18]  M. M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[19]  H. Okamoto History of discoveries and pathogenicity of TT viruses. , 2009, Current topics in microbiology and immunology.

[20]  M. Bendinelli,et al.  Immunobiology of the Torque teno viruses and other anelloviruses. , 2009, Current topics in microbiology and immunology.

[21]  Annex 4 Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products , 2003 .

[22]  Tau Fluvalinate,et al.  The European Agency for the Evaluation of Medicinal Products , 1997 .